BIOCRYST PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.2M | $26.4M | $48.3M | $13.6M | $17.3M | $26.3M | $19.6M | $62.4M |
| Cost of Revenue | $1.1M | $2.3M | $1.4M | $1.0K | — | — | — | $86.0K |
| Gross Profit | $24.0M | $24.1M | $46.9M | $13.6M | — | — | — | $62.3M |
| Gross Margin | 95.5% | 91.3% | 97.2% | 100.0% | — | — | — | 99.9% |
| Operating Expenses | ||||||||
| Research & Development | $67.0M | $61.0M | $72.8M | $51.8M | $41.9M | $49.2M | $57.2M | $83.9M |
| SG&A Expense | $13.9M | $11.3M | $13.0M | $7.5M | $6.0M | $9.1M | $12.0M | $11.7M |
| Operating Income | $-57.4M | $-48.6M | $-39.4M | $-45.8M | $-30.7M | $-33.9M | $-49.6M | $-34.4M |
| Operating Margin | -227.9% | -184.4% | -81.7% | -336.4% | -177.2% | -128.9% | -252.4% | -55.1% |
| Interest Expense | $8.6M | $6.5M | $5.2M | $5.0M | $4.8M | $4.7M | $3.8M | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $17.3M | $8.6M | $7.0M | — | — |
| Net Income | $-65.8M | $-55.1M | $-43.0M | $-45.2M | $-30.1M | $-39.1M | $-56.9M | $-33.9M |
| Net Margin | -261.2% | -209.3% | -89.1% | -332.1% | -173.7% | -148.6% | -289.9% | -54.3% |
| EPS (Basic) | $-0.78 | $-0.75 | $-0.59 | $-0.68 | $-0.55 | $-0.79 | $-1.26 | $-0.76 |
| EPS (Diluted) | $-0.78 | $-0.75 | $-0.59 | $-0.68 | $-0.55 | $-0.79 | $-1.26 | $-0.76 |
| Shares Outstanding (Basic) | — | — | — | — | — | 50.9M | 45.7M | 45.0M |
| Shares Outstanding (Diluted) | 84.5M | 73.7M | 72.9M | 66.8M | 55.2M | 50.9M | 45.7M | 45.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |